RCS - Ondine Biomedical - Mid Yorkshire NHS Trust cuts SSI rates by 71%

Ondine BiomedicalAnnouncement

02/04/2025 07:04

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250402:nRSB3135Da&default-theme=true

RNS Number : 3135D  Ondine Biomedical Inc.  02 April 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

First UK Deployment at Mid Yorkshire Teaching NHS Trust reduces SSI rates by
71% with Steriwave Nasal Photodisinfection

Ondine Biomedical Inc. (LON: OBI) reports that results from the first NHS
deployment of Steriwave(®) nasal decolonization technology at Mid Yorkshire
Teaching NHS Trust (Mid Yorks) have demonstrated a substantial reduction in
surgical site infections (SSI) following elective knee and hip replacement
surgery. A new health economic analysis conducted by the world-renowned York
Health Economics Consortium (YHEC) also found that Mid Yorks' use of Steriwave
is cost-saving for hip and knee replacement surgery.

Mid Yorks' analysis of data from a six-month period demonstrated that
Steriwave significantly reduced the combined rate of SSI in elective hip and
knee replacement surgeries by 71.4%, from a baseline rate of 1.40% to 0.42%.
The results from knee replacements were particularly impressive, showing a
reduction to zero from 2.3% (p=0.014). The number of hip replacement surgeries
during the period was insufficient for statistical analysis. In both
orthopaedic procedures, Steriwave was deployed in addition to the current
standard of care which included octenidine antiseptic nasal gel and
chlorhexidine body wash.

Using real-world data from Mid Yorks, the YHEC health economic analysis showed
that in a standardized cohort of 1,000 people, Steriwave prevents a total of
9.8 SSIs more than standard of care alone, saves £2,869 and reduces the
overall number of hospital bed days by 139.  Alongside the YHEC health
economic analysis, survey data collected at Mid Yorks revealed high levels of
satisfaction with Steriwave among both staff and patients, with a strong
likelihood of recommendation.

Carolyn Cross, CEO of Ondine Biomedical, commented:

"We commend Dr. Stuart Bond and the team at Mid Yorkshire Trust's Pontefract
Hospital for their forward-thinking approach to innovation and commitment to
tackling the persistent challenge of hospital-acquired infections and
antibiotic resistance. We anticipate that MYTT's early adoption of this
technology in the UK will serve as an influential example for healthcare
institutions globally, promoting the pursuit of improved patient outcomes and
better patient throughput while mitigating the risks associated with
antimicrobial resistance."

Steriwave is a non-invasive and painless nasal decolonization treatment that
uses a proprietary light-activated antimicrobial agent to destroy harmful
pathogens, including bacteria, viruses, and fungi, in the nose. Steriwave
treatment involves applying a proprietary photosensitive agent to each nostril
with a nasal swab, followed by illumination with a specific wavelength of red
light for five minutes. The treatment is effective immediately and takes less
than five minutes.

The YHEC economic analysis was commissioned by Health Innovation Network
Yorkshire and Humber and Ondine Biomedical as part of a project to better
understand the health economic impact of using Steriwave in the UK. Full
details of the analysis are currently being prepared for publication.

 

Enquiries:

 Ondine Biomedical Inc.                                       www.ondinebio.com
 Carolyn Cross, CEO                                          Via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 RBC Capital Markets (Broker)
 Rupert Walford, Kathryn Deegan                              +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                            +44 (0)77 1000 5910

 

 

About Ondine Biomedical Inc.

 

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies (also known as 'photodisinfection').
Ondine has a pipeline of investigational products, based on its proprietary
photodisinfection technology, in various stages of development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada and several other countries under the name Steriwave(®).
In the US, it has been granted Qualified Infectious Disease Product
designation and Fast Track status by the FDA and is currently undergoing
clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

About Mid Yorkshire Teaching NHS Trust

The UK's Mid Yorkshire Teaching NHS Trust provides acute, community and
specialist health care services to around half a million people living in
Wakefield and North Kirklees. It has three hospitals at Dewsbury, Pontefract
and Wakefield (Pinderfields), and also provide care in community settings such
as GP surgeries, health centres and clinics as well as in people's own homes.

About York Health Economics Consortium (YHEC):

York Health Economics Consortium (YHEC) is a health economic consulting
company formed in 1986 and wholly owned by the University of York. YHEC is the
University of York's main consultancy provider of health economics expertise.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPKBBNPBKKAQK